Read The Science

01 — The method

A test designed so we couldn't fool ourselves.

"Clinically tested" is a phrase anyone can print. This is what was actually behind it.

Doctors at KEM split 100 osteoarthritis patients into two groups at random. One group got 206B. The other got an oil that looked, felt and poured exactly the same — but had none of the active ingredients in it.

Then the labels came off. Neither the patients nor the doctors scoring them knew who had the real thing until the study was over.

That single rule removes the things that quietly inflate every wellness claim: hope, expectation, a clinician rooting for a result. Whatever was left at the end was the formula doing the work — or nothing at all.

02 — What it found

Four weeks in, the two groups didn't look alike anymore.

Every number below is measured against the placebo group — the fairest comparison there is.

0%

reported less pain

vs 27.7% on the look-alike oil

0%

moved more freely

vs 40.4% — measured on the WOMAC joint index

0

adverse events

across all 100 patients, both groups

Both groups began at the same place — an average pain score of 8.3 out of 10. They did not finish there.

03 — The pain curve

Pain fell on both sides. It just fell further, and kept falling, on 206B.

Patients marked their pain on a 0–10 line at the start, at two weeks, and at four. This is the average of every patient, week by week.

Average pain score (0–10)

Lower is better · n=95

206BPlacebo

The honest read: at week 2 the gap was real but slim. The two lines pulled apart over time. This is recovery behaving like recovery — not a numbing hit that fades by lunch.

04 — Moving, not just hurting

Less pain is one thing. Climbing the stairs is another.

The WOMAC index scores the boring, real stuff: stiffness in the morning, getting out of a chair, walking, putting on socks. Here's the share of each group who measurably improved by week 4.

206Bimproved on joint pain & function

89.6%

Placebosame measure, same four weeks

40.4%

Stiffness, pain and physical function were scored separately. 206B beat the placebo on all three by week 4 (p < 0.0001) — statistician's shorthand for "this almost certainly isn't chance."

05 — The realest measure

Did people still reach for a painkiller anyway?

Both groups were handed backup tablets for bad days. A questionnaire can be hopeful. Whether you still swallow the diclofenac is not. Fewer people on 206B did.

206Bneeded a backup painkiller · week 4

22.9%

Placeboneeded a backup painkiller · week 4

42.6%

Roughly half as many people on 206B needed a rescue tablet — and they took no more medicine overall. Relief that doesn't quietly add to your pill count.

06 — Day-to-day life

One group's quality of life held. The other's slipped.

The SF-12 questionnaire asks how much your health gets in the way of ordinary life. Higher is better.

Quality-of-life score (SF-12)

Higher is better · n=95

206BPlacebo

Four weeks is short for a life to visibly change. So the signal here is modest and we'll treat it that way: 206B held the line where the placebo group drifted down.

07 — In the patients' own words

At the end, we asked them to rate their own month.

Forget the indices for a second. This is how patients described their own condition after four weeks.

206B77% said good or excellent · 0% said worse

8%

15%

Good · 58%

Exc · 19%

Placebo25% said good or excellent · 11% said worse

11%

Poor · 45%

19%

15%

11%

Worse Poor Fair Good Excellent

08 — The fine print, up front

What this trial does not prove.

A study that only tells you the good parts isn't a study, it's an ad. So here are the edges of what we found.

The limits, plainly.

Read these before you read the headlines again.

01

It was an early, single-site pilot. One hospital, 100 people, four weeks. Strong enough to be worth shouting about — not large enough to be the last word. A bigger confirmatory trial is the honest next step.

02

It was tested on osteoarthritis of the knee, hip and spine, in adults aged 50–75. That's who the evidence is for. It does not, on its own, prove anything about gym soreness, a stiff neck from your laptop, or period cramps.

03

The early days were modest. At week 2 the pain difference wasn't yet statistically clear. The result built with time — which is the point, but it means 206B is not an instant fix.

04

The results are accepted for presentation at the SICOT World Orthopaedic Congress, 2026 — a serious international forum. That's a strong signal. It is not the same as being published in a peer-reviewed journal, and we won't pretend it is.

05

206B is an AYUSH-licensed herbal formulation, not a pharmaceutical. It's not a replacement for medical care. If your pain is severe, new, or not improving — see a doctor, not a label.

09 — The receipts